Tetraphase Announces Presentation at Lazard Capital Markets and Piper Jaffray & Co. Healthcare Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, today announced that the Company will present at the 7th annual Lazard Capital Markets Healthcare Conference on Wednesday, November 17th , at 2:15 pm EST at the St. Regis Hotel, the Watteau room, New York and at the Piper Jaffray & Co. 22nd Annual Healthcare Conference on Wednesday, December 1st, at 1:10 pm EST at the New York Palace Hotel in New York.

At both conferences, Guy Macdonald, President and CEO of Tetraphase, will provide an overview of the Company, its strategic objectives and review its pipeline, including its lead candidate TP-434, a novel broad-spectrum intravenous (I.V.) antibiotic with potential for oral step-down capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug-resistant gram-positive, anaerobic and atypical pathogens.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics with either broad-spectrum activity or activity more narrowly focused by indication that provide a complementary portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections. To learn more about Tetraphase, please visit www.tphase.com.



CONTACT:

Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
SVP, CFO

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.